Results 151 to 160 of about 5,286 (232)

Challenges in Implementing Revocation of Oncology Drugs Under Conditional Early Approval in Japan: Regulatory Insights From Comparisons With FDA/EMA

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Expedited pathways in the United States (U.S.), European Union (EU), and Japan (JP) enable earlier access to innovative therapies for rare and serious diseases. In 2025, Japan explicitly introduced revocation provisions to its Conditional Early Approval (CEA).
Takahiro Handa, Arata Tanaka, Mayumi Shikano, Rika Wakao   +3 more
wiley   +1 more source

Real‐World Selection of Venetoclax‐Obinutuzumab Versus BTK Inhibitor Therapy for Treatment‐Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

European Journal of Haematology, Volume 116, Issue 6, Page 845-849, June 2026.
ABSTRACT Introduction Novel targeted agents have transformed the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including continuous BTK inhibitor (BTKi) therapy and time‐limited regimens such as venetoclax‐obinutuzumab (Ven‐O) and ibrutinib‐venetoclax (I + V).
Rebecca Tidswell, Carolyn Owen, Mona Shafey, Sarah Perry, Nanette Cox‐Kennett, Russell Sterrett, Anthea Peters, Robert Puckrin   +7 more
wiley   +1 more source

Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives

European Journal of Haematology, Volume 116, Issue 6, Page 759-770, June 2026.
ABSTRACT Acalabrutinib, a second‐generation Bruton's tyrosine kinase inhibitor (BTKi), is characterized by enhanced specificity and selectivity for BTK with minimal off‐target effects, offering a significant evolution in the treatment of chronic lymphocytic leukemia (CLL). Its mechanism of action, a covalent binding to Cys481 within the BTK active site,
Gianluca Gaidano, Romano Danesi
wiley   +1 more source

Function of Bruton's tyrosine kinase during B cell development is partially independent of its catalytic activity [PDF]

, 2003
The Tec family member Bruton's tyrosine kinase (Btk) is a cytoplasmic protein tyrosine kinase that transduces signals from the pre-B and B cell receptor (BCR).
Middendorp, S., Maas, A. (Alex), Hendriks, Rudi, Maas, Alex, Dahlenborg, K., Dingjan, G.M. (Gemma), Dahlenborg, IMK, Hendriks, R.W. (Rudi), Dingjan, Gemma, Middendorp, Sabine   +9 more
core  

Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis. [PDF]

Drugs
Lambe J, Fox RJ.
europepmc   +1 more source

Visualization of a Bruton's Tyrosine Kinase Inhibitor Using Fluorescence and Raman Microscopy. [PDF]

Anal Chem
Merchant AS, Tipping WJ, Graham D, Faulds K.   +3 more
europepmc   +1 more source

Bruton's tyrosine kinase (BTK) [PDF]

Science-Business eXchange, 2010
openaire   +1 more source

Evaluation of Cardiotoxicity in Lymphoproliferative Patients Treated With Anthracycline and Bruton's Tyrosine Kinase Inhibitor-Based Regimens. [PDF]

Cureus
Bonsu A.
europepmc   +1 more source

Membrane-dependent assembly of Bruton's tyrosine kinase mediated by the Proline-rich region and SH3 domain. [PDF]

Protein Sci
Fenton AD, Chung JK.
europepmc   +1 more source

Economic Evaluation of Bruton's Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in South Africa. [PDF]

Appl Health Econ Health Policy
Woudberg R, Sinanovic E.
europepmc   +1 more source